The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.
The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.
* SAID ON THURSDAY THAT INDEPENDENT EXPECT HAD ASSESSED DEBT RESTRUCTURING PROCESS
Cambridge Chocolate Technologies S.A. :
* REPORTED ON THURSDAY FY NET LOSS $3 MILLION VERSUS LOSS $2.6 MILLION YEAR AGO
Australian shares rose on Friday, tracking gains on Wall Street after strong U.S. economic data eased concerns about a cooling economy, with financials and healthcare stocks boosting the local benchmark.
GlaxoSmithKline received a boost for its oncology research on Thursday, as it reported further positive data from a study of its experimental drug for blood cancer.
* Analysts question Biogen's growth prospects (Adds context, details, background)
Biogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.
* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES
Special Counsel Robert Mueller on Friday handed in a confidential report on his investigation into Russia's role in the 2016 presidential election and any potential wrongdoing by U.S. President Donald Trump, setting off a clamor from lawmakers in both parties for the document's quick release. Vanessa Johnston has the story.
Special Counsel Robert Mueller on Friday handed in a confidential report on his investigation into Russia's role in the 2016 presidential election and any potential wrongdoing by U.S. President Donald Trump, setting off a clamor from lawmakers in both parties for the document's quick release.